- Home
- » Tags
- » Trabectedin
Top View
- Appendix B - Product Name Sorted by Applicant
- Trabectedin Inhibits EWS-FLI1 and Evicts SWI/SNF from Chromatin in a Schedule- Dependent Manner Matt L
- Activity of Trabectedin and the PARP Inhibitor Rucaparib in Soft-Tissue
- Trabectedin for Patients with Advanced Soft Tissue Sarcoma: a Non-Interventional, Retrospective, Multicenter Study of the Italian Sarcoma Group
- Uterine Sarcoma Treatment Regimens
- Medications Used in Sarcoma Treatment
- Justification
- Trabectedin for Unresectable Or Metastatic Liposarcoma Or
- Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center
- Strategy, Efficacy and Safety of Combination Regimens Using Immunotherapy Rebecca C
- From Old Alkylating Agents to New Minor Groove Binders
- Adult Antiemetic Management of Chemotherapy-Induced Nausea
- Oncology Medications Policy (1403)
- Topotecan, Pegylated Liposomal Doxorubicin Hydrochloride
- Trabectedin Efficacy in Ewing Sarcoma Is Greatly Increased by Combination with Anti-IGF Signaling Agents
- Emetogenic Potential of Antineoplastic Agents
- Retrospective Analysis of Trabectedin Therapy for Soft Tissue Sarcoma
- Yondelis, INN-Trabectedin
- Australian Public Assessment Report for Trabectedin
- Topotecan, Pegylated Liposomal Doxorubicin Hydrochloride, Paclitaxel, Trabectedin and Gemcitabine for Treating Recurrent Ovarian Cancer
- Alkylating Anticancer Agents and Their Relations to Micrornas Bernhard Biersack
- December 2019
- Public Assessment Reports
- Yondelis® (Trabectedin)
- Reimbursement Guide
- Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products
- Viability of Microorganisms in Novel Chemical and Biopharmaceutical Anticancer Drug Solutions
- Emetic Risk of Single Intravenous Antineoplastic Agents in Adults
- Standard Oncology Criteria Policy Number: Pending
- (PDOX) Nude Mouse Model
- Clinical Review Amy Barone, MD NDA 207953 S004 YONDELIS® (Trabectedin)
- YONDELIS (Trabectedin) for Injection, for Intravenous Use Cumulative Anthracycline Dose of ≥300 Mg/M2, Age ≥65 Years, Or a History Initial U.S
- Year of FDA Monthly Cost Approval
- Global Oncology
- Drug Information in 44% of Cases (26/59) No Germ Was Isolated
- E-Learning Treatment for Relapsing Platinum Sensitive Epithelial
- Rucaparib (Rubraca) Forplatinum-Sensitive, High
- Clinically Relevant Concentrations of Anticancer Drugs: a Guide for Nonclinical Studies Dane R
- Yondelis, INN-Trabectedin
- Trabectedin: Drug Information
- A Phase II Study of Trabectedin Single Agent in Patients with Recurrent Ovarian Cancer Previously Treated with Platinum-Based Regimens Lnclstudies Clinical
- Hazardous Drug List
- Renal Impairment Hepatic Impairment Agent PK Summary Available
- National Institute for Health and Clinical Excellence
- ALT: a Multi-Faceted Phenomenon
- Trabectedin and Its Potential in the Treatment of Soft Tissue Sarcoma
- NCCN Guidelines for Soft Tissue Sarcoma V 1.2021 – Annual on 08/25/20
- Natural Product and Natural Product Derived Drugs in Clinical Trials
- Chemotherapy
- Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma